Abstract:Objective To observe the clinical effects of double plasma molecular adsorption system (DPMAS), plasma bilirubin adsorption (PBA) and Plasma exchange (PE) in liver failure, and to explore a new treatment model to replace plasma exchange. Methods A total of 40 patients with liver failure and received treatment of artificial liver in our hospital was divided into DPMAS, PBA and PE group. The biochemical indexes, adverse reactions and clinical symptoms in the three groups were observed, and multiple comparisons before and after treatment and among those three groups were conducted. Results The DPMAS and the PE group presented significant effects on total bilirubin (TBIL), direct bilirubin (DBIL), alanine aminotransferase (ALT), C reactive protein (CRP) and prothrombin activity (PTA) while the PBA group was observed to be effective on TBIL and DBIL only. The multiple comparisons among the three groups indicated that the PE group had the optimal treatment effects, followed by the DPMAS group. All three groups improved the clinical symptoms, but the PE group presented significant adverse reactions. However, the recovery rate of the DPMAS group was higher than the other two groups. Conclusions The treatment effects of DPMAS are equivalent to those of PE and have overcome the disadvantages of plasma deficiency and allergy. Only increasing the cost of equipment and consumables, DPMAS is applicable as the new model to replace plasma exchange.